Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Retained Earnings (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Retained Earnings data on record, last reported at $224000.0 in Q4 2025.

  • For Q4 2025, Retained Earnings fell 33.33% year-over-year to $224000.0; the TTM value through Dec 2025 reached $224000.0, down 33.33%, while the annual FY2025 figure was $224000.0, 33.33% down from the prior year.
  • Retained Earnings reached $224000.0 in Q4 2025 per TNGX's latest filing, up from -$564.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $336000.0 in Q4 2024 and bottomed at -$580.3 million in Q2 2025.
  • Average Retained Earnings over 5 years is -$177.8 million, with a median of -$4.6 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: crashed 949135.29% in 2021, then soared 100.07% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$161.3 million in 2021, then tumbled by 67.05% to -$269.5 million in 2022, then skyrocketed by 100.07% to $186000.0 in 2023, then skyrocketed by 80.65% to $336000.0 in 2024, then plummeted by 33.33% to $224000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $224000.0 in Q4 2025, -$564.4 million in Q3 2025, and -$580.3 million in Q2 2025.